跳至主要内容
临床试验/DRKS00000150
DRKS00000150已完成4 期

Effects of treatment with etanercept on fatigue, sleepiness, well being, sleep quality and selected immune parameters in patients with rheumatoid arthritis - Schlafprojekt

Charité - Universitätsmedizin BerlinMedizinische Klinik m.S. Rheumatologie / klinische Immunologie0 个研究点目标入组 36 人开始时间: 2009年6月19日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
36

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomized controlled study
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 70 Years(—)
性别
All

入选标准

  • Rheumatoid Arthritis according to ACR 1987 criteria;
  • age 18 - 70;
  • DAS28 geater or euqal to 3.2;
  • morning stiffness greater or equal to 30 minutes;
  • patients in etanercept group must fulfill DGRh criteria for initiation of biologic therapy;
  • patients may not have received prior biologic therapy;
  • NSAID, glucocorticoids must be at stable dosing 14 d prior to screening (gc dosing at a max of 10 mg/d prednisolon or equivalent);
  • able and willing to understand and sign informed consent;
  • able and willing to perform s.c injections themselves or having someone to do so;
  • females with reproductive potential must use adequate form of contraception

排除标准

  • Patients with history of severe disease including malignancies treated within 5 years of screening (except basal cell carcinoma of skin and squamous skin cell carcinoma and in situ carcinoma of the neck);
  • Patients with uncompensated heart insufficiency, myocardial infarction within 12 months of screening, instable angina pectoris,uncontrolled arterial hypertension, severe lung disease, history of HIV-infection, immunodeficiency syndromes, other rheumatologic disorders than RA, demyelinating CNS disease, multiple sklerosis or psychiatric disorders;
  • patients with other reasons for sleeping disorders (COLD, sleep apnea, allergic rhinitis etc.;
  • patients who received live vaccination within 4 weeks of screening;
  • patients receiving intraarticular injections with glucocorticoids within 4 weeks of screening
  • Patients receiving intramuscular or i.v. injections of glucocorticoids of euqual to or more of 10 mg/d prednisolone equivalent within 4 weeks of screening;
  • oral doses of more than 10 mg prednisolone equivalent ;
  • history of blood dyscrasias;
  • Patients with active infections or predisposing conditions for infection (e.g. leg ulcerations, untreated diabetes mellitus);
  • Patients with active Hepatitis A,B,C, Tuberculosis, chronic or latent TB, latent TB must have been adequately treated with Isoniazid 300 mg/d for 10 month starting at least 4 weeks prior to first etanercept application.
  • Renal disease or known cirrhosis or fibrosis of the liver,
  • Liver function parameters at more than 2 times of upper limit of normal range;
  • sleep associated respiratory disorder, ideopatic insomnia
  • AHI >10/h, PMLI > 5/h;
  • alcohol abuse;
  • brest feeding;
  • Patients incapable of giving informed consent

研究者

发起方
Charité - Universitätsmedizin BerlinMedizinische Klinik m.S. Rheumatologie / klinische Immunologie

相似试验